Full-Time

Regional Sales Manager

Northern California

Kuros Biosciences

Kuros Biosciences

201-500 employees

Develops bone graft solutions for healing

Compensation Overview

$120k - $150k/yr

+ Incentive compensation: $100,000-$140,000 + Total target compensation: $220,000-$290,000

Remote in USA

Remote

Remote within the territory from San Jose to southern Oregon; residence in the San Francisco Bay Area/Northern California is preferred. Up to 70% travel is required.

Bachelor's

Category
Sales & Account Management (1)
Required Skills
Sales
Forecasting
CRM

Get referred to Kuros Biosciences

See people who can refer or advise you

Requirements
  • A Bachelor's Degree or equivalent is required.
  • A minimum of 4-6 years of sales experience with a proven track record of success within fast-growing commercial teams is required.
  • The candidate must be able to work well independently and cooperatively as part of a team of professionals.
  • A quantifiable sales record for sales-related specializations in pharmaceuticals or medical devices is required.
  • Previous working experience with customer relationship management programs is required.
  • A valid driver's license with a clean driving record and adequate insurance coverage is required.
  • The candidate must be able to travel up to 70% within the territory.
  • The role may require sitting, standing, walking, climbing, reaching, bending, or stooping.
  • The role may require lifting and carrying items weighing 50 pounds or more, depending on the role.
  • Frequent use of hands and fingers is required for typing, writing, grasping, and operating office or job-specific equipment.
  • The ability to operate a motor vehicle for extended periods may be required.
Responsibilities
  • Achieve sales quotas set by the Area Sales Director independently and through distribution channels.
  • Create and execute plans to drive surgeon and distributor adoption of Kuros Biosciences bone graft solutions.
  • Develop long-lasting relationships with surgeons and distributors.
  • Serve as a consultative resource on bone biology to surgeons and distributors in the area.
  • Identify, develop, and maintain professional relationships with hospital, ambulatory surgery center, and other medical-facility value analysis and purchasing committees to participate in request-for-proposal processes.
  • Assist the Area Sales Director with recruiting and managing independent distributors.
  • Train and support distributors, including participating in field sales calls.
  • Maintain and support current business across the region, including attending surgical procedures to advise on the correct use of Kuros products.
  • Develop and implement sales plans to achieve targets.
  • Identify, develop, and maintain professional relationships with orthopedic and neurosurgical key opinion leaders in the region.
  • Identify opportunities that enhance product performance and revenue growth.
  • Develop a sustainable pipeline using company customer relationship management and forecasting tools.
  • Follow up on marketing actions and provide feedback on market campaigns and messaging.
  • Maintain industry awareness of market trends, competition, product acceptance, and new product releases.
  • Maintain organization and operational excellence in delivering Kuros services and products to surgeon customers and commercial business partners.
  • Understand and comply with internal and external procedures to maintain supply-chain operations and product delivery.
  • Participate in and assist with commercial and marketing efforts as requested.
  • Provide sales forecasts and tactical plans as directed by the Area Sales Director.
  • Provide regular progress and key-issue reports to the Area Sales Director and colleagues.
  • Create, update, and maintain a customer database and contact records.
  • Give presentations to surgeons and staff.
  • Provide support at key events in the United States.
  • Represent the company to third-party contacts and associates.
  • Work effectively as part of the sales team and with the wider Kuros organization.
  • Maintain learning and knowledge exchange through regular contact with colleagues.
  • Work to continually improve Kuros's reputation as a science-driven company.
Desired Qualifications
  • A clinical background and experience are highly preferred.
  • Medical or hospital credentialing is preferred.
  • Prior experience in spine surgery and osteobiologics is strongly preferred.

Kuros Biosciences develops and commercializes advanced bone graft solutions for bone healing and regeneration, primarily serving hospitals and clinics for spinal fusion and other orthopedic procedures. Its products, like MagnetOs and Fibrin PTH, use proprietary materials and formulations that actively influence the bone healing process to improve outcomes and lower the risk of non-unions. The company differentiates itself by focusing on a specialized niche within medical technology, validating effectiveness and safety through ongoing research, clinical trials, and partnerships that help bring targeted bone graft therapies to healthcare providers. Kuros’s goal is to enhance patient recovery and outcomes in bone-related surgeries while expanding access to proven graft-based healing solutions.

Company Size

201-500

Company Stage

IPO

Headquarters

Zurich, Switzerland

Founded

2000

Get referred to Kuros Biosciences

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 sales rose 51% to $43.4 million; EBITDA stayed positive.
  • 2025 revenue jumped 72% to $146.1 million; Kuros posted first-ever profit.
  • Alpharetta production starts second half 2026, supporting 2026 35% growth guidance.

What critics are saying

  • Cash fell to $15.7 million in Q1 2026 while capacity spending continued.
  • MagnetOs generated $143.9 million of 2025 sales; concentration risks remain extreme.
  • One manufacturing delay in Alpharetta would jam 2026 growth and margin expansion.

What makes Kuros Biosciences unique

  • MagnetOs dominates sales with 87% gross margin and 51% Q1 2026 growth.
  • Alpharetta Georgia manufacturing facility localizes US supply, reducing import friction.
  • I.V. Hall’s DePuy Synthes trauma and extremities expertise deepens musculoskeletal expansion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Wellness Program

Stock Options

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
May 12th, 2026
Kuros Biosciences drops 25.6% YTD — but DCF model suggests 70% undervaluation at $22.43

Kuros Biosciences shares have declined 0.8% over the past week and 17.1% over the past year, despite strong three-year gains exceeding 10-fold. The stock currently trades at CHF 19.85, with a valuation score of 4 out of 6. A discounted cash flow analysis estimates the company's intrinsic value at US$66.17 per share, suggesting the stock is 70% undervalued at current levels. The Swiss biotech company recorded a free cash flow loss of US$2.65 million over the latest twelve months. Analyst projections anticipate free cash flow reaching US$30.02 million in 2026 and US$73.42 million in 2028, extending to 2035. The valuation relies heavily on these future cash flow expectations rather than current cash generation. The recent pullback has prompted investors to reassess whether the stock still offers value.

Associated Press
May 7th, 2026
Kuros Biosciences appoints I.V. Hall as COO to strengthen extremities R&D leadership

Kuros Biosciences, a leader in bone healing technologies, has appointed I.V. Hall as chief operating officer effective 1 June 2026. Hall succeeds Sjoerd Musters, who will remain through 1 August to ensure a smooth transition. Hall brings over 30 years of medical device experience, including 27 years at DePuy Synthes (Johnson & Johnson), where he served as global president of trauma, extremities and craniomaxillofacial businesses. Most recently, he was CEO of Next Science, leading commercialisation of surgical infection prevention solutions. The appointment supports Kuros' expansion across musculoskeletal applications and pipeline development, particularly in extremities. Chief executive Chris Fair said Hall's experience building R&D-driven organisations aligns with the company's strategic plan to translate scale into operational leverage.

Associated Press
Apr 14th, 2026
Kuros Biosciences reports 51% sales growth to $43.4M in Q1 2026

Kuros Biosciences, a Swiss bone healing technology company, reported total product sales of $43.4 million in the first quarter of 2026, up 51% from $28.8 million in Q1 2025. Direct MagnetOs product sales rose 51% to $42.9 million. The company achieved group EBITDA of $2.9 million, compared to $2.0 million in Q1 2025. Adjusted EBITDA reached $5.7 million, representing a 13.1% margin. Cash and cash equivalents totalled $15.7 million, down from $19.8 million at year-end 2025, reflecting investments in production capacity expansion. Kuros saw strong growth in minimally invasive surgery procedures and extremities applications. A retrospective study published in Spine Open reported an 87% fusion rate for MagnetOs Easypack Putty in high-risk posterior lumbar fusion patients. The company's new US manufacturing facility in Alpharetta, Georgia, remains on track for production in the second half of 2026.

Yahoo Finance
Apr 6th, 2026
European growth stocks with insider ownership show up to 58% earnings growth potential

Kuros Biosciences, a Swiss musculoskeletal care company, is highlighted among European growth stocks with high insider ownership. The firm focuses on commercialising biologic technologies across the United States and European Union, with a market capitalisation of CHF898.68 million. The company generates revenue through its medical devices segment, which brought in $146.06 million. Kuros is amongst 213 fast-growing European companies identified in a recent screener, selected during a period when the STOXX Europe 600 Index rose 3.92%. The analysis comes as investor sentiment improves amid hopes of a shorter Middle East conflict and robust gains in major indices including Germany's DAX and the UK's FTSE 100. High insider ownership typically signals strong confidence from company leadership.

Yahoo Finance
Mar 10th, 2026
Kuros Biosciences posts first-ever profit with 72% sales growth to $146.1M

Kuros Biosciences, a leader in bone healing technologies, reported 72% year-over-year sales growth, reaching $146.1 million for 2025, up from $85.2 million in 2024. Direct MagnetOs sales increased 71% to $143.9 million. The company achieved its first-ever net profit of $2.6 million, compared to a $4.8 million loss in 2024. Group EBITDA reached $12.4 million, whilst adjusted EBITDA hit $19.6 million with a 13.4% margin. Cash and cash equivalents stood at $19.8 million. For 2026, Kuros expects at least 35% sales growth with an adjusted EBITDA margin around 14%. By 2028, the company anticipates sales between $300 million and $330 million with an adjusted EBITDA margin of at least 20%.